Prot #DSP-5336-101: A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) Rearrangement or Nucleophosmin

Project: Research project

Project Details

StatusActive
Effective start/end date3/17/253/17/28

Funding

  • Sunovion Pharmaceuticals Inc. (Prot #DSP-5336-101)